Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GSK plc (GSK) vs VICI Properties Inc (VICI) Price & Performance

VICI Properties IncTrade

Price performance (Past 24H)

Key statistics

GSK plc vs VICI Properties Inc — how do they compare? GSK plc trades at $50.42 (market cap $102.60B), while VICI Properties Inc trades at $26.09 (market cap $28.61B). The key difference: GSK plc is far larger — about 3.6× VICI Properties Inc's market cap, and VICI Properties Inc pays the higher dividend (6.93%). Which is the better fit depends on your goals.

GSKVICI
Market Cap
$102.60B$28.61B
Sector
HealthReal Estate
52-Week High
$61.18$33.78
52-Week Low
$38.22$25.94
Enterprise Value
$123.04B$46.16B
Dividend Yield
3.57%6.93%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GSK plc

GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.

GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.

VICI Properties Inc

VICI Properties trades at $26.03, down 0.17% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals with a P/E of 10.07, net income margin of 67.5%, and a recent dividend of $0.45 paid in July 2026. Q2 2026 earnings saw an EPS miss at $0.48 versus $0.713 expected, though revenue beat forecasts, and the company raised its AFFO guidance.

Analyst consensus is strongly bullish with a $29.83 price target and 76.9% buy ratings, highlighting the 6.6% dividend yield and solid cash flow. Key risks include high debt levels, interest expense pressure, and uncertainty from the Caesars acquisition overhang, but the REIT's tangible assets and oligopoly advantages support long-term income appeal.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK

About VICI Properties Inc

VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.

Read more on VICI